Trillium Therapeutics Doses First Patient With Checkpoint Inhibitor TTI-622

Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL) announced on 6/14/2018 that it has initiated dosing in its phase 1 clinical trial of TTI-622 (SIRPaFc-IgG4), a checkpoint inhibitor of the innate immune system, in relapsed or refractory lymphoma or myeloma.